Mapping of the structural gene of pseudorabies virus glycoprotein A and identification of two non-glycosylated precursor polypeptides

Aujeszky's Disease and the Development of the Marker/DIVA Vaccination Concept

Aujeszky's disease or pseudorabies is an infection of animals caused by Suid alphaherpesvirus 1, also designated as pseudorabies virus (PrV). Whereas many mammals are susceptible to PrV, only pigs are able to survive productive infection. Early reports on this disease originate from cattle and companion animals with the hallmark sign of "mad itch", meaning development of pruritus. Although first reports date back to the early 19th century, it was Aladár Aujeszky who in 1902 described this disease, which has since been named after him, as a separate entity. AD expanded in the 20th century, despite efforts to control this infection in the growing pig farming industry. Live-attenuated vaccines were developed in the early 1960s, which assisted early eradication efforts. A major breakthrough in animal vaccinology occurred in the mid-1980s, when it was found that several live-attenuated PrV vaccine strains lacked a significant portion of the genome, including the gene encoding a major immunogenic viral envelope glycoprotein. Upon the development of a suitable serological assay, the first marker vaccine/DIVA concept (differentiating infected from vaccinated animals) was developed. Moreover, the first genetically modified live vaccines emanated from molecular work on PrV. Thus, AD serves as a hallmark for the history of veterinary virology as well as for pioneering novel strategies for controlling animal infectious diseases.

Vaccines against pseudorabies virus (PrV)

Aujeszkýs disease (AD, pseudorabies) is a notifiable herpesvirus infection of pigs causing substantial economic losses to swine producers. AD in pigs is controlled by the use of vaccination with inactivated and attenuated live vaccines. Starting with classically attenuated live vaccines derived from low virulent field isolates, AD vaccination has pioneered novel strategies in animal disease control by the first use of genetically engineered live virus vaccines lacking virulence-determining genes, and the concept of DIVA, i.e. the serological differentiation of vaccinated from field-virus infected animals by the use of marker vaccines and respective companion diagnostic tests. The basis for this concept has been the molecular characterization of PrV and the identification of so-called nonessential envelope glycoproteins, e.g. glycoprotein E, which could be eliminated from the virus without harming viral replication or immunogenicity. Eradication of AD using the strategy of vaccination-DIVA testing has successfully been performed in several countries including Germany and the United States. Furthermore, by targeted genetic modification PrV has been developed into a powerful vector system for expression of foreign genes to vaccinate against several infectious diseases of swine, while heterologous vector systems have been used for expression of major immunogens of PrV. This small concise review summarizes the state-of-the-art information on PrV vaccines and provides an outlook for the future.

Characterization and structural features of a chalcone synthase mutation in a white-flowering line of Matthiola incana R. Br. (Brassicaceae)

For Matthiola incana (Brassicaceae), used as a model system to study biochemical and genetical aspects of anthocyanin biosynthesis, several nearly isogenic colored wild type lines and white-flowering mutant lines are available, each with a specific defect in the genes responsible for anthocyanin production (genes e, f, and g). For gene f supposed to code for chalcone synthase (CHS; EC 2.3.1.74), the key enzyme of the flavonoid/anthocyanin biosynthesis pathway belonging to the group of type III polyketide synthases (PKS), the wild type genomic sequence of M. incana line 04 was determined in comparison to the white-flowering CHS mutant line 18. The type of mutation in the chs gene was characterized as a single nucleotide substitution in a triplet AGG coding for an evolutionary conserved arginine into AGT coding for serine (R72S). Northern blots and RT-PCR demonstrated that the mutated gene is expressed in flower petals. Heterologous expression of the wild type and mutated CHS cDNA in E. Scherichia coli, verified by Western blotting and enzyme assays with various starter molecules, revealed that the mutant protein had no detectable activity, indicating that the strictly conserved arginine residue is essential for the enzymatic reaction. This mutation, which previously was not detected by mutagenic screening, is discussed in the light of structural and functional information on alfalfa CHS and related type III PKS enzymes.

Identification and characterization of pseudorabies virus glycoprotein gM as a nonessential virion component

Sequence analysis within BamHI fragment 3 of the pseudorabies virus (PrV) genome revealed an open reading frame homologous to the UL10 gene of herpes simplex virus. A rabbit antiserum directed against a synthetic oligopeptide representing the carboxy-terminal 18 amino acids of the predicted UL10 product recognized a major 45-kDa protein in lysates of purified Pr virions. In addition, a second protein of 90 kDa which could represent a dimeric form was observed. Enzymatic deglycosylation showed that the PrV UL10 protein is N glycosylated. Therefore, it was designated PrV gM according to its homolog in herpes simplex virus. A PrV mutant lacking ca. 60% of UL10 coding sequences was able to productively replicate on noncomplementing cells, demonstrating that PrV gM is not required for viral replication in cell culture. However, infectivity of the mutant virus was reduced and penetration was delayed, indicating a modulatory role of PrV gM in the initiation of infection.

Construction of bovine herpesvirus-1 (BHV-1) recombinants which express pseudorabies virus (PRV) glycoproteins gB, gC, gD, and gE

We have improved the method for constructing recombinants of bovine herpesvirus type-1 (BHV-1). Using this method, we constructed three recombinants in which the pseudorabies virus (PRV) thymidine kinase (tk) gene was inserted at three different sites in the unique short region of BHV-1. These three sites are located in the open reading frame of gE, gG and gI genes. Previously, two sites (tk and gC) had been used to insert foreign DNA fragments to BHV-1 genome. Therefore we now have 5 sites in BHV-1 where DNA can be inserted. The gB, gC, gD, gE and gI genes of PRV were successfully inserted at the tk or the gC gene of BHV-1 genome and Western blot analyses confirmed that the recombinants express PRV gB, gC, gD and gE. Anti-PRV gB and gC antibodies as well as anti-PRV polyclonal serum neutralized BHV-1 recombinants which express PRV gB and gC. The latter was neutralized more strongly. However, anti-gD monoclonal antibody and anti-PRV polyclonal serum failed to neutralize gD-expressing recombinants. This suggests that PRV gC and some gB are integrated into the viral envelope of the recombinants, but very little gD is present in the viral envelope.

Glycoprotein E of pseudorabies virus and homologous proteins in other alphaherpesvirinae

This paper reviews biological properties of glycoprotein E (gE) of pseudorabies virus (Aujeszky's disease virus) and homologous proteins in other alphaherpesvirinae. It focuses on the gene encoding gE, conserved regions in the gE protein and its homologs, the complex of gE and gI, biological functions of gE in vitro and in vivo, the role of gE in latency and the role of gE in the induction of humoral and cellular immune responses. Special emphasis is placed on the use of gE as a marker protein in the control and eradication of pseudorabies virus.

Specific pseudorabies virus infection of the rat visual system requires both gI and gp63 glycoproteins

Transneuronal transport of pseudorabies virus (PRV) from the retina to visual centers that mediate visual discrimination and reflexes requires specific genes in the unique short region of the PRV genome. In contrast, these same viral genes are not required to infect retinorecipient areas of the brain involved in circadian rhythm regulation. In this report, we demonstrate that viral mutants carrying defined deletions of the genes encoding glycoprotein gI or gp63, or both, result in the same dramatic transport defect. Efficient export of either gI or gp63 from the endoplasmic reticulum to the Golgi apparatus in a fibroblast cell line requires the presence of both proteins. We also show that gI and gp63 physically interact, as demonstrated by pulse-chase and sucrose gradient sedimentation experiments. Complex formation is rapid compared with homodimerization of PRV glycoprotein gII. We suggest that gI and gp63 function in concert to affect neurotropism in the rat visual circuitry and that a heterodimer is likely to be the unit of function.

Protection of mice and swine from pseudorabies virus conferred by vaccinia virus-based recombinants

Glycoproteins gp50, gII, and gIII of pseudorabies virus (PRV) were expressed either individually or in combination by vaccinia virus recombinants. In vitro analysis by immunoprecipitation and immunofluorescence demonstrated the expression of a gII protein of approximately 120 kDa that was proteolytically processed to the gIIb (67- to 74-kDa) and gIIc (58-kDa) mature protein species similar to those observed in PRV-infected cells. Additionally, the proper expression of the 90-kDa gIII and 50-kDa gp50 was observed. All three of these PRV-derived glycoproteins were detectable on the surface of vaccinia virus-PRV recombinant-infected cells. In vivo, mice were protected against a virulent PRV challenge after immunization with the PRV glycoprotein-expressing vaccinia virus recombinants. The coexpression of gII and gIII by a single vaccinia virus recombinant resulted in a significantly reduced vaccination dose required to protect mice against PRV challenge. Inoculation of piglets with the various vaccinia virus-PRV glycoprotein recombinants also resulted in protection against virulent PRV challenge as measured by weight gain. The simultaneous expression of gII and gp50 in swine resulted in a significantly enhanced level of protection as evaluated by weight evolution following challenge with live PRV.

Identification and characterization of pseudorabies virus glycoprotein H

On the basis of DNA sequence analysis, it has recently been shown that the pseudorabies virus (PrV) genome encodes a protein homologous to glycoprotein H (gH) of other herpesviruses (B. Klupp and T.C. Mettenleiter, Virology 182:732-741, 1991). To obtain antibodies specific for gH(PrV), rabbits were immunized with synthetic peptides representing two potential epitopes on gH(PrV) as predicted by computer analysis. The antipeptide sera recognized the gH precursor polypeptide pgH translated in vitro from an in vitro-transcribed mRNA. Western blot (immunoblot) analyses of purified pseudorabies virions using these antisera revealed specific reactivity with a protein with an apparent molecular mass of 95 kDa. Specificity of the reaction could be demonstrated by competition experiments with respective peptides. Analysis of PrV deletion mutants defective in genes encoding known glycoproteins proved that gH(PrV) constitutes a novel PrV glycoprotein not previously found. Treatment of purified virion preparations with endoglycosidase H reduced the apparent molecular mass of gH(PrV) to 90 kDa, indicating the presence of N-linked high-mannose (or hybrid) carbohydrates in mature virions. Removal of all N-linked carbohydrates by N-glycosidase F resulted in a product of 76 kDa. In summary, our results demonstrate the existence of gH in PrV as a structural component of the virion.

The gIII glycoprotein of pseudorabies virus is involved in two distinct steps of virus attachment

The entry of herpesviruses into cells involves two distinct stages: attachment or adsorption to the cell surface followed by internalization. The virus envelope glycoproteins have been implicated in both stages. Pseudorabies virus attaches to cells by an early interaction that involves the viral glycoprotein gIII and a cellular heparinlike substance. We examined the role of gIII in the attachment process by analysis of a set of viruses carrying defined gIII mutations. The initial attachment of gIII mutants with an internal deletion of 134 amino acids (PrV2) to MDBK cells was indistinguishable from that of wild-type virus. The adsorption of these mutants was, however, much more sensitive than that of wild-type virus to competing heparin. Furthermore, while attachment of wild-type virus to MDBK cells led to a rapid loss of sensitivity to heparin, this was not the case with PrV2, which could be displaced from the cell surface by heparin after it had attached to the cells. We conclude that glycoprotein gIII is involved in two distinct steps of virus attachment and that the second of these steps but not the first is defective in PrV2.

Sequence and expression of the glycoprotein gH gene of pseudorabies virus

In the pseudorabies virus (PrV) genome a gene equivalent to the glycoprotein gH gene of other herpesviruses was identified and sequenced. It is located immediately downstream from the gene encoding PrV thymidine kinase within genomic BamHI fragments 11 and 16. Nucleotide sequencing allowed deduction of the amino acid sequence of gH. The primary translation product is predicted to comprise 686 amino acids and to exhibit a molecular weight of 71.9 kDa. It possess several characteristics typical for membrane glycoproteins, including a N-terminal hydrophobic signal sequence, C-terminal transmembrane and cytoplasmic domains, and domains with high surface probability containing three potential N-linked glycosylation sites. Comparison to other herpesvirus gH proteins revealed amino acid sequence homologies varying from 39% to gH (BHV-1), 28% to gH (HSV-1), and 19% to gH (EBV). Transcriptional analysis revealed a 2.3-kb mRNA as the gH-specific transcript. In vitro translation of either in vitro transcribed or hybrid-selected mRNA confirmed both the location of the gH gene and the size of the gH primary translation product (pgH).

Linker insertion mutagenesis of herpesviruses: inactivation of single genes within the Us region of pseudorabies virus

We describe a technique for the systematic inactivation of nonessential genes within the genome of a herpesvirus without the requirement for phenotypic selection. This technique is based on the insertion of an oligonucleotide containing translational stop codons at a random site within a large cloned viral DNA fragment. Mutant virus is then reconstituted by cotransfection with overlapping viral clones, together comprising the entire viral genome, as described previously (M. van Zijl, W. Quint, J. Briaire, T. de Rover, A. Gielkens, and A. Berns, J. Virol. 62:2191-2195, 1988). This technique was used to construct, in a single experiment, a set of 13 viable pseudorabies virus strains with oligonucleotide insertions within all known genes of the Us region except for the gp50 gene, which proved essential for virus growth in cell culture. The growth rate in porcine kidney cells of mutants of all nonessential Us genes was similar to that of the parental virus, with the exception of a mutant of the recently identified protein kinase gene.

Marker vaccines, virus protein-specific antibody assays and the control of Aujeszky's disease

Vaccination of pigs is widely practised to control Aujeszky's disease (AD). Molecular biological research revealed that several conventionally attenuated virus vaccines harbour deletions in their genomes. The deleted genes are nonessential for virus replication and can be involved in the expression of virulence. These findings have prompted several groups to construct well-characterized deletion mutants of AD virus that do not express either glycoprotein gI, gX or gIII. These mutants have also been rendered thymidine kinase negative. Although data on vaccine efficacy and safety have been published, widely varying test conditions have made it impossible to identify the most efficacious deletion mutant vaccine(s). Vaccination enhances the amount of virus required for infection and reduces, but does not prevent, the shedding of virulent virus and the establishment of latency in pigs infected with virulent AD virus. Therefore, while a vaccination programme will reduce the circulation of virus in the field, it will not eliminate AD virus from pig populations. To eradicate AD, the ability to differentiate infected from vaccinated pigs is crucial. The use of marker vaccines enables us to identify infected pigs in vaccinated populations by detecting antibodies against the protein whose gene is deleted from vaccine strains. The antibody response to gI appears to persist for more than 2 years, and all of about 300 field strains tested so far express gI. The use of vaccines lacking gI in combination with an enzyme linked immunosorbent assay to detect antibodies to gI and culling of gI-seropositive pigs, may help to eradicate AD in countries where vaccination is widely practised.

Identification of pseudorabies virus-exposed swine with a gI glycoprotein enzyme-linked immunosorbent assay

A monoclonal antibody specific for the gI glycoprotein of virulent pseudorabies virus was produced and used to affinity purify gI glycoprotein. The purified gI was used in an enzyme-linked immunosorbent assay (ELISA) that identified and differentiated field virus-exposed animals from animals vaccinated with gI-deleted virus. The gI ELISA was evaluated by comparing it with the virus neutralization test and with a standard ELISA which does not distinguish between vaccinated and naturally infected animals. Pigs vaccinated with a gI-deleted vaccine were seropositive by the virus neutralization or standard ELISA but were seronegative in the gI ELISA. Nonvaccinated and vaccinated animals were detected as seropositive in the gI ELISA only after exposure to gI-containing field virus. Exposed animals were detected as early as day 7 and for as long as 141 days after field virus exposure. As little as 10(2.7) PFU of field virus was sufficient to seroconvert negative animals in the gI ELISA. Pseudorabies virus-seronegative animals which received multiple doses of gI-deleted vaccine remained seronegative in the gI ELISA. The use of this test to monitor swine for pseudorabies virus infection would offer significant benefits towards eradication of the disease.

Biological evaluation of glycoproteins mapping to two distinct mRNAs within the BamHI fragment 7 of pseudorabies virus: expression of the coding regions by vaccinia virus

Several glycoproteins from the unique short region of pseudorabies have been identified and characterized. The genes encoding at least four glycoproteins (gp50, gp63, gl, and gX) are located within the BamHI fragment 7 of pseudorabies. S1 nuclease mapping was used to determine that a 2.4-kb mRNA encompasses the coding region for gp50 and gp63 and probably represents a colinear transcript for these proteins. Using the same technique, a 2.8-kb mRNA was found to encode gl. No other mRNAs were found to be encoded on the opposite strand of DNA in this region. Various recombinant vaccinia vectors were made incorporating the coding regions for these two mRNAs. Pseudorabies recombinant vaccinia infected ST cells expressed glycoproteins that co-migrated with the authentic PRV glycoproteins upon polyacrylamide electrophoresis. Intracranial or intraperitoneal inoculation of mice with the recombinant viruses constructed to contain the mRNA coding regions resulted in various degrees of protection from a lethal challenge of pseudorabies virus.

Molecular pathogenesis of equine coital exanthema: identification and expression of infected cell polypeptides at the restricted temperature during equine herpesvirus 3 infection

Equine herpesvirus 3 (EHV-3)-infected equine cells display a kinetics of infected cell polypeptide (ICP) synthesis at 34 degrees C that is typical of coordinate cascade gene regulation of herpesviruses. In contrast, when infected cell cultures are incubated at the restricted temperature of 39 degrees C, the shift from early (beta) gene expression to late (gamma) gene expression is perturbed, i.e., there is an accumulation of early (beta) gene products and a decrease in, or absence of, late (gamma) gene products. Some of the affected late (gamma) gene products may be glycoproteins since these ICPs co-migrated with radiolabeled bands from infected cells incubated with [3H] glucosamine, separated by polyacrylamide gel electrophoresis. These findings are consistent with previous findings (Jacob, 1986), indicating that the growth restriction is in a late viral function(s) and possibly involves envelopment of nucleocapsids into infectious virions.

New approaches to animal vaccines utilizing genetic engineering

Control of infectious diseases in livestock is an important determinant in the success of a nation's effort to efficiently meet its need for animal products. Genetic engineering offers many new options in the design of animal vaccines. Monoclonal antibodies, DNA cloning, recombination, and transfection are examples of techniques that facilitate innovative strategies in antigen identification, production, and delivery. This article reviews the use of genetic engineering in the production of vaccines directed against foot-and-mouth disease virus and other important pathogens of animals. The advantages and disadvantages of vaccines produced through the use of genetic engineering are discussed.

Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells

Pseudorabies virus (PRV) is an alphaherpesvirus which causes an economically important disease of swine. One of the PRV glycoproteins, gp50, was previously identified as the sequence homolog of herpes simplex virus glycoprotein gD (E.A. Petrovskis, J.G. Timmins, M.A. Armentrout, C.C. Marchioli, R.J. Yancey, Jr., and L.E. Post, J. Virol. 59:216-223, 1986). gp50 was evaluated as a PRV subunit vaccine candidate. gp50 protected mice from PRV-induced mortality either when delivered via infection with a recombinant vaccinia virus or when administered as a subunit vaccine produced in a eucaryotic cell line, Chinese hamster ovary (CHO) cells. In addition, gp50 synthesized in CHO cells protected pigs from lethal infection with PRV. This result demonstrates that a single viral glycoprotein could induce a protective immune response in the natural host of a herpesvirus infection.

The pseudorabies virus gII gene is closely related to the gB glycoprotein gene of herpes simplex virus

We have looked for conserved DNA sequences between four herpes simplex virus type 1 (HSV-1) glycoprotein genes encoding gB, gC, gD, and gE and pseudorabies virus (PRV) DNA, HSV-1 DNA fragments representing these four glycoprotein-coding sequences were hybridized to restriction enzyme fragments of PRV DNA by the Southern blot procedure. Specific hybridization was observed only when HSV-1 gB DNA was used as probe. This region of hybridization was localized to a 5.2-kilobase (kb) region mapping at approximately 0.15 map units on the PRV genome. Northern blot (RNA blot) analysis, with a 1.2-kb probe derived from this segment, revealed a predominant hybridizing RNA species of approximately 3 kb in PRV-infected PK15 cells. DNA sequence analysis of the region corresponding to this RNA revealed a single large open reading frame with significant nucleotide homology with the gB gene of HSV-1 KOS 321. In addition, the beginning of the sequenced PRV region also contained the end of an open reading frame with amino acid homology to HSV-1 ICP 18.5, a protein that may be involved in viral glycoprotein transport. This sequence partially overlaps the PRV gB homolog coding sequence. We have shown that the PRV gene with homology to HSV-1 gB encoded the gII glycoprotein gene by expressing a 765-base-pair segment of the PRV open reading frame in Escherichia coli as a protein fused to beta-galactosidase. Antiserum, raised in rabbits, against this fusion protein immunoprecipitated a specific family of PRV glycoproteins of apparent molecular mass 110, 68, and 55 kilodaltons that have been identified as the gII family of glycoproteins. Analysis of the predicted amino acid sequence indicated that the PRV gII protein shares 50% amino acid homology with the aligned HSV-1 gB protein. All 10 cysteine residues located outside of the signal sequence, as well as 4 of 6 potential N-linked glycosylation sites, were conserved between the two proteins. The primary protein sequence for HSV-1 gB regions known to be involved in the rate of virus entry into the cells and cell-cell fusion, as well as regions known to be associated with monoclonal antibody resistance, were highly homologous with the PRV protein sequence. Furthermore, monospecific antibody made against PRV gII immunoprecipitated HSV-1 gB from infected cells. Taken together, these findings suggest significant conservation of structure and function between the two proteins and may indicate a common evolutionary history.

Role of pseudorabies virus glycoprotein gI in virus release from infected cells

The Bartha vaccine strain of pseudorabies virus has a deletion in the short unique (Us) region of its genome which includes the genes that code for glycoproteins gI and gp63 (E. Petrovskis, J. G. Timmins, T. M. Gierman, and L. E. Post, J. Virol. 60:1166-1169, 1986). Restoration of an intact Us to the Bartha strain enhances its ability to be released from infected rabbit kidney cells and increases the size of the plaques formed on these cells (T. Ben-Porat, J. M. DeMarchi, J. Pendrys, R. A. Veach, and A. S. Kaplan, J. Virol. 57:191-196, 1986). To determine which gene function plays a role in virus release from rabbit kidney cells, deletions were introduced into the genomes of both wild-type virus and the "rescued" Bartha strain (Bartha strain to which an intact Us had been restored) that abolish the expression of either the gI gene alone or both gI and gp63 genes. The effect of these deletions on the phenotype of the viruses was studied. Deletion mutants of wild-type virus defective in either gI or gI and gp63 behave like wild-type virus with respect to virus release and plaque size on rabbit kidney cells. Deletion of gI from the rescued Bartha strain, however, strongly affects virus release and causes a decrease in plaque size. We conclude that gI affects virus release but that at least one other viral function also affects this process. This function is defective in the Bartha strain but not in wild-type virus; in its absence gI is essential to efficient release of the virus from rabbit kidney cells.

Induced proteins in cells infected with pseudorabies virus

New proteins appearing after infection of cultured L929 cells with pseudorabies virus (PRV) were analyzed by SDS polyacrylamide gel electrophoresis. Analysis was facilitated by using a virus-cell system with marked inhibition of host protein synthesis after infection. Infected cells were pulsed during successive two hour periods through the infectious cycle with 35S-methionine. Proteins were extracted with detergent and analyzed on high resolution reducing gels. Thirty-four protein bands were resolved on gels of different concentrations that varied from 7 to 15 percent. Calculated apparent molecular weights of the protein peaks were not dependent on gel concentration except for very large or small sized proteins. Eight glycoproteins were resolved after labeling with 14C-glucosamine. The time course of incorporation of label was used as a measure of protein synthesis allowing the grouping of proteins according to the time of maximal synthesis. Several proteins shifted in MW during the course of infection, indicating possible post-translational cleavage or other minor modification.

Variability of pseudorabies virus glycoprotein I expression

The 130,000 mol wt glycoprotein I (gI) derived from two approx 80-kDa precursors is one of the major constituents of the envelope of pseudorabies virus (PRV) strain Phylaxia. Recently, gI has been shown to be nonessential for PRV replication since several PRV vaccine strains with deletions in the region of the genome encoding the gI gene have been described. In this paper we demonstrate that other alterations affecting gI expression can occur. We describe a PRV field isolate which expresses a single gI precursor molecule pgI of 64,000 mol wt. This precursor is processed into 60,000 mol wt gI. In contrast to PRV Phylaxia, the gI-expressing isolate is not neutralized by anti-gI monoclonal antibodies. Virions expressing the pgI also emerged after serial in vitro passages of the wild-type PRV strain NIA-5 which initially expressed wild-type pgI. Concomitant with the appearance of pgI the pgI disappeared and the resistance of the virus population to neutralization by anti-gI monoclonal antibodies increased. Furthermore, the amount of expression of gI and pgI in single plaque isolates of the PRV strain Ka was found to be highly variable among different plaque isolates and correlated with a different susceptibility to neutralization by anti-gI monoclonal antibodies. In single plaque isolates of strain Phylaxia, however, gI expression appeared to be stable. In all cases, no genomic or transcriptional alterations could be observed. Thus, viruses resistant to anti-gI antibodies occur spontaneously in vivo and in vitro, which argues against the use of gI as a subunit vaccine.

Deletions in vaccine strains of pseudorabies virus and their effect on synthesis of glycoprotein gp63

The pseudorabies virus vaccine strains Norden and Bartha each have been reported to have deletions in the small unique component of the genome (B. Lomniczi, M. L. Blankenship, and T. Ben-Porat, J. Virol. 49:970-979, 1984). The deletion in Norden was shown to delete the entire coding region for gI but not any of the coding sequences for gp63. However, gp63 in Norden-infected cells was only 36 kilodaltons, and a 44-kilodalton form of gp63 was released into the medium. In Bartha, the deletion removed the coding region for all but 89 amino acids of gp63, and no gp63 was detected in either Bartha-infected cells or medium.

Role of glycoproteins of pseudorabies virus in eliciting neutralizing antibodies

The experiments described in this paper were designed to assess the role of the various virus glycoproteins of pseudorabies virus (PrV) in eliciting the production of neutralizing antibodies during the normal course of infection of swine. They also address the question of the degree of antigenic variation within each glycoprotein between different virus isolates. The results show the following: Antigenic variation between strains of PrV isolated from different geographic areas are readily detectable; antigenic differences between strains isolated from the same geographic area are less common. No antigenic drift in glycoprotein gII was observed. Glycoprotein gIII and, to some extent, also glycoprotein gI showed a high level of antigenic drift. The neutralizing activity of pooled convalescent sera of swine is not directed against glycoprotein gI. A large part of the neutralizing activity of pooled convalescent sera of swine is directed against glycoprotein gIII.

Use of lambda gt11 to isolate genes for two pseudorabies virus glycoproteins with homology to herpes simplex virus and varicella-zoster virus glycoproteins

A library of pseudorabies virus (PRV) DNA fragments was constructed in the expression cloning vector lambda gt11. The library was screened with antisera which reacted with mixtures of PRV proteins to isolate recombinant bacteriophages expressing PRV proteins. By the nature of the lambda gt11 vector, the cloned proteins were expressed in Escherichia coli as beta-galactosidase fusion proteins. The fusion proteins from 35 of these phages were purified and injected into mice to raise antisera. The antisera were screened by several different assays, including immunoprecipitation of [14C]glucosamine-labeled PRV proteins. This method identified phages expressing three different PRV glycoproteins: the secreted glycoprotein, gX; gI; and a glycoprotein that had not been previously identified, which we designate gp63. The gp63 and gI genes map adjacent to each other in the small unique region of the PRV genome. The DNA sequence was determined for the region of the genome encoding gp63 and gI. It was found that gp63 has a region of homology with a herpes simplex virus type 1 (HSV-1) protein, encoded by US7, and also with varicella-zoster virus (VZV) gpIV. The gI protein sequence has a region of homology with HSV-1 gE and VZV gpI. It is concluded that PRV, HSV, and VZV all have a cluster of homologous glycoprotein genes in the small unique components of their genomes and that the organization of these genes is conserved.

Equine herpesvirus genomes: heterogeneity of naturally occurring type 4 isolates and of a type 1 isolate after heterologous cell passage

The restriction endonuclease DNA fingerprints of 20 low passage, epidemiologically unrelated isolates of equine herpesvirus 4 (equine rhinopneumonitis virus) showed considerable heterogeneity in certain fragments, the positions of which were assigned to quite restricted positions on the 141 kilobase (kb) genome. We note that the heterogeneity observed in the restriction endonuclease DNA fingerprints of EHV 1 (equine abortion virus) and of pseudorabies virus also tend to map to these same restricted regions. The restriction endonuclease DNA fingerprints of an EHV 1 strain was invariant using low (less than 1) multiplicity of infection during 20 passages in equine cells but when adapted to hamster cells developed an approximately 0.8 kb deletion in the unique short region of the genome between 8 and 11 passages.

Pseudorabies virus gene encoding glycoprotein gIII is not essential for growth in tissue culture

We have established that in the Becker strain of pseudorabies virus (PRV), the glycoprotein gIII gene is not essential for growth in cell culture. This was accomplished by construction and analysis of viral mutants containing two defined deletion mutations affecting the gIII gene. These mutations were first constructed in vitro and introduced into Escherichia coli expression plasmids to verify structure and protein production. Each mutation was then crossed onto PRV by cotransfection of plasmid DNA and parental viral DNA by using gIII-specific monoclonal antibodies as selective and screening reagents. One resultant virus strain, PRV-2, contained an in-frame deletion of a 402-base-pair (bp) SacI fragment contained within the gIII gene. Another virus strain, PRV-10, contained a deletion of a 1,480-bp XhoI fragment removing 230 bp of the upstream, putative transcriptional control sequences and 87% of the gIII coding sequence. The deletion mutants were compared with parental virus by analysis of virion DNA, gIII specific RNA, and proteins reacting with gIII specific antibodies. Upon infection of PK15 cells, the deletion mutants did not produce any proteins that reacted with two gIII specific monoclonal antibodies. However, two species of truncated glycosylated proteins were observed in PRV-2 infected cells that reacted with antiserum raised against bacterially produced gIII protein. PRV-10 produced no detectable gIII-specific RNA or protein. PRV-10 could be propagated without difficulty in tissue culture. Virus particles lacking gIII were indistinguishable from parental PRV virus particles by analysis of infected-cell thin sections in the electron microscope. We therefore conclude that expression of the gIII gene was not absolutely essential for PRV growth in tissue culture.

DNA sequence of the gene for pseudorabies virus gp50, a glycoprotein without N-linked glycosylation

The DNA sequence was determined for a region of the pseudorabies virus (PRV) genome to which a mutation defining resistance to a monoclonal antibody has been mapped (M. W. Wathen and L. M. K. Wathen, J. Virol., 51:57-62, 1984). This sequence was found to contain an open reading frame that did not include an amino acid sequence directing N-linked glycosylation. This open reading frame was expressed in uninfected Chinese hamster ovary cells to produce the PRV glycoprotein gp50. When PRV-infected Vero cells were incubated in the presence of tunicamycin, the gp50 that was produced had an identical molecular weight to that produced in the absence of drug. When infected cells were incubated in the presence of monensin, the molecular weight of gp50 was reduced from 60,000 to 45,000, but was not sensitive to endo-beta-N-acetylglucosaminidase H. These observations led to the conclusion that gp50 does not contain N-linked carbohydrate, as predicted from the DNA sequence. A region of the amino acid sequence and the positions of the cysteine residues of PRV gp50 are homologous to glycoprotein D of herpes simplex virus.

Location of the structural gene of pseudorabies virus glycoprotein complex gII

The glycoprotein gII, one of the major glycoproteins of pseudorabies virus (PRV), is represented by a complex of three related glycopolypeptides. There is evidence that two of them, linked by disulfide bonds, arise by proteolytic cleavage of the larger precursor glycoprotein. Using specific antisera and a monoclonal antibody against the glycoprotein complex one single nonglycosylated in vitro translated precursor polypeptide with mol wt 110,000 was identified. Mapping of the gene coding for this polypeptide was achieved by hybrid selection of late viral RNA on cloned DNA fragments. The structural gene for the gII complex was found to reside in the long unique part of the PRV genome on BamHI fragment 1 and SalI subfragments 1A and G (map units 0.105 to 0.130). A 3.5-kb mRNA was identified as the probable gII-specific transcript. In addition, further polypeptides encoded in the BamHI fragment 1 were described and RNAs were characterized by Northern blot hybridizations with the cloned SalI subfragments.

Characterization of a pseudorabies virus glycoprotein gene with homology to herpes simplex virus type 1 and type 2 glycoprotein C

A pseudorabies virus (Becker strain) glycoprotein gene was located in the UL region at map position 0.40. The gene was identified by using open reading frame Escherichia coli plasmid expression vectors and specific antibody reagents. A 1.55-kilobase unspliced transcript from the gene was detected in pseudorabies virus-infected tissue culture cells. The DNA sequence revealed a single open reading frame of 1,437 base pairs encoding 479 amino acids. The predicted primary translation product has a molecular weight of 50,860 and contains features of a typical herpesvirus glycoprotein. An E. coli expression plasmid was constructed that contained essentially all of the open reading frame for this gene. Antibodies raised in rabbits against the protein expressed in bacteria by this plasmid immunoprecipitated pseudorabies virus-specific glycoproteins of 92,000 and 74,000 daltons from infected cell extracts. It is likely that these two forms represent different glycosylation states of the protein.

Characterization and mapping of a nonessential pseudorabies virus glycoprotein

Antigenic variants of pseudorabies virus (PRV) containing mutations in a viral glycoprotein with a molecular weight of 82,000 (gIII) were isolated by selecting for resistance to a complement-dependent neutralizing monoclonal antibody (MCA82-2) directed against gIII. These mutants were completely resistant to neutralization with MCA82-2 in the presence of complement. Two mutants selected for further studies either did not express gIII or expressed an improperly processed form of the glycoprotein. The mutations were also associated with an altered plaque morphology (syncytium formation). The gIII gene was mapped by marker rescue of a gIII- mutant with cloned restriction enzyme fragments to the long unique region of the PRV genome between 0.376 and 0.383 map units. This corresponds to the map location of a glycoprotein described by Robbins et al. (J. Mol. Appl. Gen. 2:485-496, 1984). Since gIII is nonessential for viral replication in cell culture and has several other characteristics in common with the herpes simplex virus glycoprotein gC, gIII may represent the PRV equivalent to herpes simplex virus gC.

Genetic relatedness and colinearity of genomes of equine herpesvirus types 1 and 3

The arrangement and location of homologous DNA sequences within the genomes of equine herpesvirus type 1 (EHV-1) and EHV-3 were investigated by using Southern blot hybridization analyses conducted under stringent conditions. Recombinant plasmid libraries comprising 95 and 84% of the EHV-1 and EHV-3 genomes, respectively, were labeled with 32P-deoxynucleotides by nick translation and were used as probes in filter hybridization studies. The DNA homology between the EHV-1 and EHV-3 genomes was dispersed throughout the genomes in a colinear arrangement. Significant hybridization was detected between the EHV-1 short region inverted repeat sequences, which are known to encode immediate early transcripts, and the corresponding EHV-3 inverted repeat sequences. Interestingly, probes derived from the EHV-1 heterogeneous region, which is adjacent to the EHV-1 short region, hybridized strongly to EHV-3 DNA sequences within a similar genomic location, but did not reveal any corresponding heterogeneity within the EHV-3 genome. Our results demonstrated that there is a highly conserved evolutionary relationship between EHV-1 and EHV-3 and provided the foundation for further investigations to determine whether similarities in protein function underpin the genetic relatedness between these two herpesviruses.

Construction of an infectious pseudorabies virus recombinant expressing a glycoprotein gIII-beta-galactosidase fusion protein

An infectious herpesvirus mutant has been constructed in which a major structural envelope glycoprotein gene was replaced by a hybrid gene encoding a novel fusion protein consisting of the N-terminus of the viral glycoprotein joined to Escherichia coli beta-galactosidase (beta Gal). Specifically, we fused DNA encoding the first 157 amino acids of the structural glycoprotein gIII from pseudorabies virus strain Becker to the E. coli lacZ gene in a bacterial expression vector. The resulting hybrid gene was then used to replace the wild-type gIII gene in the virus by cotransfection of plasmid and viral DNA. The desired viral recombinants were identified by their inability to react with specific monoclonal antibodies that recognized only wild-type gIII protein. One such mutant virus, PRV-Z1, was chosen for further analysis. PRV-Z1 expressed a glycosylated gIII-beta Gal fusion protein after infection of PK15 cells. The fusion protein has no demonstrable beta Gal activity and, although glycosylated, remains sensitive to the enzyme endo-beta-N-acetylglucosaminidase H, unlike the mature gIII gene product, indicating that the fusion protein was incompletely processed.

Proteins specified by the short unique region of the genome of pseudorabies virus play a role in the release of virions from certain cells

Two pseudorabies virus vaccine strains (Bartha and Norden) that have a similar deletion in the short unique (Us) region of the genome have been identified previously (B. Lomniczi, M. L. Blankenship, and T. Ben-Porat, J. Virol. 49:970-979, 1984). These strains do not code for the glycoprotein gI, a glycoprotein that has been mapped on the wild type virus genome by T. C. Mettenleiter, N. Lukacs, and H. J. Rziha (J. Virol. 53:52-57, 1985) to the sequences deleted from the vaccine strain. Restoration of these deleted sequences to the Bartha strain genome restores to the virus the ability to specify the gI glycoprotein. The Bartha vaccine strain grows as well as wild-type virus in pig kidney and in rabbit kidney (RK) cells, but is not released efficiently from and forms small plaques in RK cells. The rescued Bartha 43/25a strain (which has an intact Us) is released considerably more efficiently than the Bartha vaccine strain, but less efficiently than wild-type virus from RK cells; it also forms larger plaques on RK cells than does the parental Bartha vaccine strain. The Norden vaccine strain, which has a deletion in the Us, is released better from RK cells than is the Bartha strain, but not as well as is wild-type virus. We conclude that whereas the sequences in the Us that are deleted from the Bartha and Norden strain genomes specify functions that play a role in the release of virions from some cell types, at least one other function (which is defective in the Bartha strain but not in the Norden strain) also affects release of virus from these cells. Since restoration to the Bartha strain of an intact Us restores to the virus both the ability to grow in chicken brains (B. Lomniczi, S. Watanabe, T. Ben-Porat, and A. S. Kaplan, J. Virol. 52:198-205, 1984) and to be released from RK cells, the possibility that the lack of virulence of the Bartha vaccine strain may be related to its limited release from some target cells is discussed.

Pseudorabies virus avirulent strains fail to express a major glycoprotein

The unique short (Us) region of the pseudorabies virus (PRV) genome, which displays high transcriptional activity during the late phase of infection and has been found to code for glycoproteins, is partially deleted in the genomes of three vaccine strains (A57, Norden, and NIA-4). This deletion is located in the SalI subfragment 7A of BamHI fragment 7. To identify possible viral gene products involved in PRV virulence, we investigated the transcriptional and translational pattern of the deleted part of the Us region. Northern blots demonstrated that one major RNA species (3.8 kilobases) transcribed from fragment 7A was missing in the vaccine strains, whereas other transcripts were altered. Radioimmunoprecipitation of in vivo-labeled PRV glycoproteins and of in vitro-translated polypeptides with hyperimmune serum and monoclonal antibodies indicated a lack of glycoprotein gI. Hybrid-selection experiments with subcloned DNA fragments confirmed the absence of gI and of a 40,000-molecular-weight polypeptide. We suggest that both viral proteins are involved in the expression of PRV virulence.

Demonstration of three major species of pseudorabies virus glycoproteins and identification of a disulfide-linked glycoprotein complex

The glycoproteins of pseudorabies virus (PRV) Phylaxia were characterized with monoclonal antibodies as specific reagents. Three major structural glycoproteins with molecular weights of 155,000 (155K) (gC), 122K (gA), and 90K (gB) could be identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions. We investigated the processing of glycoproteins gA, gB, and gC by in vitro translation, pulse-chase experiments, and in the presence of the ionophore monensin which inhibits glycosylation. gA and gB were found to compose a single polypeptide, whereas gC was found to be a disulfide-linked glycoprotein complex. Immunoprecipitates formed with the aid of anti-gC monoclonal antibodies gave rise to three glycoprotein bands (gC0 [120K], gC1 [67K], and gC2 [58K]) by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions. Limited proteolysis of gC0, gC1, and gC2 resulted in peptide maps of gC0 related to those of both gC1 and gC2. No common peptide bands between gC1 and gC2, however, were seen. We suggest that (i) gC1 and gC2 arise by proteolytic cleavage from the same precursor molecule and stay joined via disulfide bridges and (ii) gC0 is an uncleaved precursor.